(Contact Info: larry at larryblakeley.com)
Important Note: You will need to click this icon to download the free needed to view most of the images on this Web site - just a couple of clicks and you're "good to go." For reasons why - go here.
A listing and access link to all:
song lyrics and mp3 audio files http://www.royblakeley.name/larry_blakeley/songs/ (all of which are a part of this Web site) can be accessed simply by selecting the "htm" file for the song you want;
quotations http://www.royblakeley.name/larry_blakeley/quotations.htm; and
essays written by Larry Blakeley http://www.royblakeley.name/larry_blakeley/articles/articles_larry_blakeley.htm,
all of which are used to tell the story in this Web site, can be accessed by going to each respective link set out above.
My son, Larry Blakeley http://www.royblakeley.name/larry_blakeley/larryblakeley_photos_jpeg.htm manages this Web site and the following Web sites:
Larry Blakeley (Contact Info: larry at larryblakeley.com)
Leslie (Blakeley) Adkins - my granddaughter
Lori Ann Blakeley (June 20, 1985 - May 4, 2005) - my granddaughter
Evan Blakeley- my grandson
Major Roy James Blakeley (December 10, 1928 - July 22, 1965) - USAF (KIA)
When I was young my dad would say
Come on son let's go out and play
No matter how hard I try
No matter how many tears I cry
No matter how many years go by
I still can't say goodbye
- "I Still Can't Say Goodbye," Performer: Chet Atkins
MP3 audio file/lyrics http://www.royblakeley.name/larry_blakeley/songs/still_cant_say_goodbye.htm
For a larger image click on the photograph.
Background Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in current phase 1 oncology trials.
Methods We reviewed all nonpediatric phase 1 oncology trials sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute between 1991 and 2002. We report the rates of response to treatment, of stable disease, of grade 4 toxic events, and of treatment-related deaths.
Results We analyzed 460 trials involving 11,935 participants, all of whom were assessed for toxicity and 10,402 of whom were assessed for a response to therapy. The overall response rate (i.e., for both complete and partial responses) was 10.6 percent, with considerable variation among trials. "Classic" phase 1 trials of single investigational chemotherapeutic agents represented only 20 percent of the trials and had a response rate of 4.4 percent. Studies that included at least one anticancer agent approved by the Food and Drug Administration constituted 46.3 percent of the trials and had a response rate of 17.8. An additional 34.1 percent of participants had stable disease or a less-than-partial response. The overall rate of death due to toxic events was 0.49 percent. Of 3465 participants for whom data on patient-specific grade 4 toxic events were available, 14.3 percent had had at least one episode of grade 4 toxic events.
Conclusions Overall response rates among phase 1 oncology trials are higher than previously reported, although they have not changed for classic phase 1 trials, and toxicity-related death rates have remained stable. Rates of response and toxicity vary, however, among the various types of phase 1 oncology trials.
- "Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002," Elizabeth Horstmann, B.A., Mary S. McCabe, R.N., M.A., Louise Grochow, M.D., Seiichiro Yamamoto, Ph.D., Larry Rubinstein, Ph.D., Troy Budd, Dale Shoemaker, Ph.D., Ezekiel J. Emanuel, M.D., Ph.D., and Christine Grady, R.N., Ph.D., Volume 352:895-904, March 3, 2005, Number 9 http://content.nejm.org/cgi/content/abstract/352/9/895
File Name: risks_benefits_phase_1_oncology_trials200503_abstract.htm
Post Date: March 4, 2005 at 7:20 AM CST; 1320 GMT